Author: admin

It’s time to mark your calendars—stock markets will be closed this Wednesday, December 25, in observance of Christmas. That means no action in the equity, derivatives, or SLB segments, and the multi-commodity exchange will also take a breather for both morning and evening sessions. So, if you were thinking of squeezing in some last-minute trades, you’ll have to wait until Thursday. Looking ahead, the market holiday schedule for 2025 looks a little different. There will be 14 trading holidays, down from 16 in 2024. Some months will have one holiday each (February, May, November, and December), while March and August will feature two. Expect three trading holidays in April and October. The first holiday of the new year will fall on February 26 for Mahashivratri, so plan accordingly. Interestingly, some holidays coincide with weekends in 2025—Republic Day (January 26), Shri Ram Navami (April 6), and Muharram (July 6) all fall on Sundays, while Bakri Id will be on Saturday, June 7. These weekend holidays may affect trading patterns, so keep an eye on how they might impact market activity.

TVS Motor Company is stepping into the spotlight after announcing that it has completed a major acquisition, bringing its stake in DriveX Mobility to a commanding 87.38%. The details of the transaction are still a bit murky—TVS revealed it acquired 39.11% of DriveX, or 7,914 equity shares, from existing shareholders. Regardless, this marks a significant consolidation of power in DriveX, a digital-first auto-tech company that’s been carving out a niche in the booming pre-owned two-wheeler market across India. This deal isn’t TVS’s first brush with DriveX—back in August 2022, the company picked up a 48.27% stake in DriveX’s parent, Nkars Mobility Millennial Solutions. Now, with this latest move, TVS is clearly doubling down on its commitment to the pre-owned two-wheeler space. As for TVS Motor’s stock, it’s had a decent run, up 21.35% in the past year and 18.3% year-to-date. But over the last few months, there’s been a bit of a slowdown—down 16% in the last three months and a slight dip of 1% in the past month. TVS closed flat at Rs 2,388.15 in the previous session, but this fresh development with DriveX could reignite some investor enthusiasm.

Angel One has certainly had a bumpy ride recently, with its stock price plummeting by an 8% dive this past week. After a high of Rs 3,500, the stock now finds itself hovering around Rs 2,900—well off its peak but not without some potential hope for a bounce-back. The key takeaway here is that the stock is hovering near some important support levels. On the daily chart, it’s holding up above the lower end of its rising channel, with the previous swing low of around Rs 2,600 still intact. This suggests that, while the recent pullback has been sharp, there’s still a technical case for a rebound. Angel One’s technical picture shows a stock that could consolidate in the near term before finding its way back up. The critical Rs 2,700-2,800 zone will be the one to watch for clues about the next direction, with the potential for an upward move if it holds. The stock may have fallen over the past year, but in the last six months, it’s gained a solid 12.3%, and the short-term volatility could be the foundation for a possible recovery. 

Shares of Bharat Forge are set to attract attention following the company’s announcement of a $64.5 million capital infusion into its U.S.-based subsidiaries. The move, approved by the company’s Strategic Business Investment Committee on December 23, 2024, is aimed at strengthening its operations in the United States and reducing debt burdens across its entities. According to the stock exchange filing, Bharat Forge will allocate $19.5 million directly to Bharat Forge America (BFA). Of the remaining funds, $30 million will flow into Bharat Forge Aluminum USA, a wholly owned subsidiary of BFA, and $15 million into Bharat Forge PMT Technologie, another fully owned entity under BFA. All three companies will use the capital for repaying or prepaying outstanding borrowings, thereby enhancing their financial flexibility. While the stock has delivered long-term gains, rising 7.9% over the past year and 4% in 2024 to date, it has faced notable pressure in recent months. Over the last six months, the share price has fallen 26%, with a 3-month decline of 18.11%.

Aarti Drugs shares staged a dramatic recovery on Tuesday, surging 11.12% and breaking an eight-day losing streak. The stock, which opened at ₹425.95 after Monday’s close at ₹423.95, remained flat through most of the session. But a late-hour rally saw it skyrocket to an intraday high of ₹495.55 before settling at ₹471.10, making it the top gainer among group A stocks. The surge came on the heels of an announcement that Aarti Drugs received an Establishment Inspection Report (EIR) from the USFDA for its API manufacturing facility in Tarapur, Maharashtra. The report confirmed that the facility, which produces key APIs like Ciprofloxacin HCl, Zolpidem Tartrate, and Celecoxib, is classified as “voluntary action indicated” (VAI). This rating signifies minimal compliance issues and clears the way for exports to the lucrative US market. Despite Tuesday’s gains, Aarti Drugs has had a tough year, with the stock down 4% year-to-date. If the upward momentum continues, December could mark the end of a prolonged losing streak.

Greaves Cotton shares electrified the market on Tuesday, jumping nearly 10% after its subsidiary, Greaves Electric Mobility Limited, revealed plans for a ₹1,000 crore IPO. The company filed a Draft Red Herring Prospectus (DRHP) with SEBI, BSE, and NSE on December 23, 2024, marking a significant step toward strengthening its foothold in the electric mobility space. The IPO will include a fresh issue of equity shares and an offer for sale by major stakeholders, including Abdul Latif Jameel Green Mobility Solutions DMCC and Greaves Cotton itself. On the BSE, Greaves Cotton shares opened at ₹236.80, shot up to ₹256.30 intraday, and touched a low of ₹229.70. The stock has been on a robust upward trajectory, surging from ₹160 to ₹260 in November alone. Greaves Cotton’s bold strategy highlights its commitment to innovation and scaling up in the electric vehicle sector, a market with immense potential. This IPO not only promises to solidify its market position but also serves as a rallying point for investors eager to ride the EV wave.

The Securities and Exchange Board of India (SEBI) cracked down hard on Bharat Global Developers Ltd., suspending trading of its shares over accusations of manipulating stock prices with fake disclosures and accounting fraud. The Gujarat-based firm allegedly fabricated claims of securing massive orders from big names like Reliance Industries, Tata Group, and McCain India Agro, which propelled its shares by a staggering 10,000% in just a year. SEBI’s investigation revealed these “high-value orders” were smoke and mirrors, strategically timed to benefit a select group of investors who participated in preferential share offerings. This is just the latest in a string of fraud cases targeting India’s vibrant but increasingly risky equity market. The regulator recently tightened rules for smaller company listings to curb such abuses, canceling IPOs and delaying others amidst allegations of shady dealings. SEBI’s actions against Bharat Global include barring involved parties from the capital markets and impounding illicit gains.

Tata Group stocks lit up the BSE on December 24, riding a wave of excitement over reports that the conglomerate is preparing to launch the IPO of its financial services arm, Tata Capital. Tata Investment Corporation soared 12%, while Tata Technologies climbed 4%. Other Tata entities joined the party, with Tata Chemicals up 3%, Tata Motors rising 2%, and TCS inching up 1%. According to a Moneycontrol report, the group is already in talks with advisors for this blockbuster IPO, likely exceeding ₹15,000 crore. The IPO would fulfill the Reserve Bank of India’s (RBI) mandate requiring “upper-layer” non-banking financial companies (NBFCs) to list within three years of notification. The group has reportedly engaged legal powerhouse Cyril Amarchand Mangaldas and investment bank Kotak Mahindra Capital to lead the charge. This IPO is expected to be a show-stopper, given Tata Capital’s strong positioning in India’s financial ecosystem. Its compliance with RBI norms not only underscores the group’s adaptability but also reflects its strategic intent to leverage public markets for growth.

PG Electroplast shares surged 5.5% in early trading on December 24, hitting ₹1,002, as the company announced a strategic tie-up with Whirlpool of India. The agreement, revealed through a regulatory filing, positions PG Electroplast as a contract manufacturer for select Whirlpool-branded semi-automatic washing machines. PG Electroplast has cemented its reputation as a leading player in India’s electronic manufacturing services (EMS) space, working with top consumer durables and electronics brands. They’re betting on expanded capacities and capabilities to sustain their dominance in the consumer durables and plastics sector. To match this optimism, the company revised its FY25 revenue guidance to ₹4,250 crore—a remarkable 54.7% jump from FY24 levels. Net profit projections are equally ambitious, expected to climb 82.5% year-over-year to ₹250 crore. Operational efficiencies and robust cash flow management underpin these forecasts.

Biocon’s shares soared 5% on Tuesday, December 24, closing at ₹344.80 after hitting an intraday high of ₹347.35. The rally was fueled by two significant developments that strengthened investor confidence in the company’s growth trajectory. The first boost came from the United States Food and Drug Administration (USFDA), which issued an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) status for Biocon’s Active Pharmaceutical Ingredients (API) facility in Bengaluru. Adding further momentum, Biocon announced that its European partner, Zentiva, received a decentralised procedure approval in the European Union (EU) for Liraglutide, a complex formulation used to treat Type-2 diabetes and manage weight. Biocon’s stock, which has already gained 35% year-to-date, reflected the optimism around these developments. The Bengaluru-based biopharma giant is clearly on a roll, leveraging strategic partnerships and regulatory approvals to solidify its presence in both the API and biosimilar markets.